Geode Capital Management
OVID icon

Geode Capital Management’s Ovid Therapeutics OVID Stock Holding History

Geode Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Buy
4,072,653
+2,754,562
+209% +$7.11M ﹤0.01% 2488
2026
Q1 		$2.93M Buy
1,318,091
+646,087
+96% +$1.16M ﹤0.01% 2984
2025
Q4 		$1.1M Buy
672,004
+23,984
+4% +$36.9K ﹤0.01% 3346
2025
Q3 		$843K Buy
648,020
+4,685
+0.7% +$4.06K ﹤0.01% 3439
2025
Q2 		$212K Sell
643,335
-687,658
-52% -$207K ﹤0.01% 3855
2025
Q1 		$415K Buy
1,330,993
+1,558
+0.1% +$958 ﹤0.01% 3612
2024
Q4 		$1.24M Buy
1,329,435
+12,105
+0.9% +$13.5K ﹤0.01% 3288
2024
Q3 		$1.55M Buy
1,317,330
+14,816
+1% +$15.5K ﹤0.01% 3201
2024
Q2 		$1M Buy
1,302,514
+42,435
+3% +$118K ﹤0.01% 3305
2024
Q1 		$3.84M Buy
1,260,079
+27,156
+2% +$90.9K ﹤0.01% 2841
2023
Q4 		$3.97M Buy
1,232,923
+32,146
+3% +$110K ﹤0.01% 2825
2023
Q3 		$4.61M Sell
1,200,777
-12,308
-1% -$44.2K ﹤0.01% 2679
2023
Q2 		$3.98M Buy
1,213,085
+713,450
+143% +$2.42M ﹤0.01% 2814
2023
Q1 		$1.29M Hold
499,635
– – ﹤0.01% 3235
2022
Q4 		$929K Buy
499,635
+7,562
+2% +$12.9K ﹤0.01% 3377
2022
Q3 		$905K Buy
492,073
+3,637
+0.7% +$7.61K ﹤0.01% 3437
2022
Q2 		$1.05M Sell
488,436
-5,422
-1% -$13.1K ﹤0.01% 3398
2022
Q1 		$1.55M Sell
493,858
-80,003
-14% -$252K ﹤0.01% 3384
2021
Q4 		$1.84M Buy
573,861
+22,959
+4% +$78.7K ﹤0.01% 3403
2021
Q3 		$1.85M Buy
550,902
+100,378
+22% +$366K ﹤0.01% 3384
2021
Q2 		$1.76M Sell
450,524
-313,313
-41% -$1.24M ﹤0.01% 3321
2021
Q1 		$3.07M Buy
763,837
+192,103
+34% +$638K ﹤0.01% 3035
2020
Q4 		$1.32M Buy
571,734
+1,816
+0.3% +$8.46K ﹤0.01% 3274
2020
Q3 		$3.27M Sell
569,918
-17,840
-3% -$119K ﹤0.01% 2627
2020
Q2 		$4.33M Buy
587,758
+293,721
+100% +$1.37M ﹤0.01% 2420
2020
Q1 		$876K Buy
294,037
+6,108
+2% +$20.6K ﹤0.01% 3070
2019
Q4 		$1.19M Buy
287,929
+60,887
+27% +$192K ﹤0.01% 3218
2019
Q3 		$735K Hold
227,042
– – ﹤0.01% 3350
2019
Q2 		$420K Buy
227,042
+6,354
+3% +$11.3K ﹤0.01% 3529
2019
Q1 		$390K Buy
220,688
+124,823
+130% +$312K ﹤0.01% 3531
2018
Q4 		$231K Buy
95,865
+6,391
+7% +$29.2K ﹤0.01% 3627
2018
Q3 		$507K Buy
89,474
+12,186
+16% +$92.4K ﹤0.01% 3461
2018
Q2 		$602K Buy
77,288
+27,269
+55% +$234K ﹤0.01% 3373
2018
Q1 		$353K Buy
50,019
+16,070
+47% +$130K ﹤0.01% 3519
2017
Q4 		$335K Buy
33,949
+50
+0.1% +$459 ﹤0.01% 3500
2017
Q3 		$290K Buy
33,899
+6,057
+22% +$50.4K ﹤0.01% 3539
2017
Q2 		$292K Buy
+27,842
New +$364K ﹤0.01% 3550

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management's OVID Position: Q2 2026 in Review

Geode Capital Management increased its Ovid Therapeutics (OVID) stake by 209% in Q2 2026, buying an estimated $7.11M and bringing the position to 4,072,653 shares worth $11M. The position accounts for ﹤0.01% of the portfolio, ranked #2488.

Geode Capital Management first reported a position in OVID in Q2 2017 and has held it in 37 quarters since. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Geode Capital Management held 4,072,653 shares of Ovid Therapeutics worth $11M as of Q2 2026.
  • Geode Capital Management bought 2,754,562 Ovid Therapeutics shares in Q2 2026, an estimated $7.11M.
  • Ovid Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2488 holding.
  • Geode Capital Management first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 37 quarters since.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.